iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $109.99 per share for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2025-08-14
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2025-03-31 was $78.00, a 1508.25% increase year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.85, a 9.18% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2023-03-31 was $5.34, a 320.47% increase year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.27.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $5.00, a 15.25% decline from fiscal 2022.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $5.90, a 6.94% decline from fiscal 2021.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2021 was $6.34.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-06-30 | $109.99 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $78.00 10-Q · filed 2025-05-19 | |||
| 2024-12-31 | $102.66 10-Q · filed 2025-08-14 | |||
| 2024-09-30 | $110.04 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $5.27 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $4.85 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $5.00 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $4.99 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $5.29 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $5.34 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $5.90 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $5.20 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $5.03 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $1.27 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $6.34 10-K/A · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |